BioVie Inc. Direct Offering Announcement
BioVie Inc. (NASDAQ: BIVI), a clinical-stage biopharmaceutical company focused on developing therapeutic solutions for serious medical conditions, recently disclosed the pricing details of a registered direct offering. This offering involves 1,146,000 shares of its common stock, priced at $2.83 per share, aiming to raise approximately $3.2 million in gross proceeds before expenses.
Use of Proceeds from the Offering
With the fundraising from this offering, BioVie plans to allocate the net proceeds primarily for working capital and other general corporate purposes. This strategic move is essential to support the company's ongoing research and development efforts and to enhance its operational capabilities.
Closing Timeline of the Offering
The company anticipates that the registered direct offering, along with a concurrent private placement, will conclude shortly after the announcement, subject to meeting standard closing conditions.
Thinking Equity’s Role as Placement Agent
In this offering, ThinkEquity is acting as the sole placement agent. Their involvement is instrumental in facilitating this direct offering, thereby helping BioVie strengthen its financial position to continue its vital work in drug development.
Company’s Clinical Focus and Innovative Therapies
BioVie Inc. has been at the forefront of innovation, developing drug therapies for chronic conditions, particularly focusing on neurological disorders and advanced liver disease. Their key drug candidate, bezisterim, has shown promise in modulating neuroinflammation associated with diseases like Alzheimer’s and Parkinson’s. This molecule specifically targets inflammatory pathways while preserving essential cellular functions, highlighting BioVie’s commitment to tackling significant health challenges effectively.
Drug Development for Neurodegenerative Disorders
As part of their initiative, BioVie is exploring the impacts of persistent neuroinflammation seen in conditions like Post-Acute Sequelae of SARS-CoV-2 infection (commonly known as Long COVID). The company’s ongoing research could pave the way for advanced treatment options for those facing the repercussions of such debilitating diseases.
Orphan Drug Designation and Clinical Trials
In the realm of liver disease, BioVie’s innovative therapy BIV201 has been granted Orphan drug designation and received Fast Track status from the FDA. This therapy focuses on treating patients with liver cirrhosis and ascites, aiming to mitigate the risk of further complications. The company is currently in discussions with the FDA regarding the design of Phase 3 clinical trials, a critical step forward for BIV201.
Contact Information for Further Inquiries
For investor relations, Bruce Mackle, Managing Director at LifeSci Advisors, is available for inquiries at bmackle@lifesciadvisors.com. For media relations, Melyssa Weible from Elixir Health Public Relations can be contacted at mweible@elixirhealthpr.com, ensuring that inquiries from both the investment community and the media are promptly addressed.
Frequently Asked Questions
What is the total amount raised through the direct offering?
BioVie Inc. raised approximately $3.2 million through the direct offering.
What is the price per share in this offering?
The shares were priced at $2.83 each under the offering.
Who is the placement agent for this offering?
ThinkEquity is acting as the sole placement agent for the offering.
What are the primary uses for the proceeds from this offering?
The net proceeds will primarily be used for working capital and general corporate purposes.
What therapies is BioVie developing?
BioVie is developing innovative therapies for neurodegenerative disorders and liver disease, such as its drug candidates targeting Alzheimer’s, Parkinson’s, and complications from advanced liver disease.
